新功能、新界面、新体验,扫描即可下载生物谷APP!
首页 » BIOON报道 » 百特公司40亿美元兼并案获得中国批准

百特公司40亿美元兼并案获得中国批准

来源:生物谷 2013-08-17 22:05

2013年8月17日讯 /生物谷BIOON/ --百特公司赢得了中国政府关于其40亿美元收购金宝公司的收购案的批准。这也标准着公司朝着全球肾脏透析领导者的目标又迈出重要一步。而作为对百特公司收购案许可的条件,中国政府提出了两个条件。第一,百特公司必须将旗下的持续性肾脏替代疗法部门出售;第二,公司必须在2016年3月前终止其与日本公司Nipro在中国的外包协议。

此前,百特公司已经获得了欧盟对其收购计划的批准。为其兼并计划扫清了很多障碍。公司现在在肾脏透析领域占有举足轻重的位置,其上一季度肾脏医疗器械收入达到了6亿5千万,一旦兼并Gambro公司成功,公司将获得其在拉丁美洲和亚洲的广阔客户基础。(生物谷Bioon.com)

详细英文报道:

Baxter ($BAX) has won over Chinese regulators with its proposed $4 billion deal for Gambro, completing the latest stop in a world tour to become a global leader in kidney dialysis.

China had just two conditions to approve Baxter's deal, Reuters reports: First, the company has to sell off its continuous renal replacement therapy segment, and then it has until March 2016 to get out of a China-based outsourcing deal with Japan's Nipro.

Baxter already promised the EU it would ditch the renal replacement business in exchange for a conditional deal approval last month, and the company will have to do without a segment that includes devices to treat acute kidney failure and accounts for about 2% of total kidney sales.

With the penciled-in blessings from the EU and China, Baxter is a bit closer to leapfrogging current dialysis market leader Fresenius Medical ($FMS) and, assuming it doesn't have to shed too many units in the process, taking the top spot in the renal market.

Baxter is already well-situated in dialysis, last quarter raking in $654 million from its renal devices, a 3% jump over the previous year. But adding in Gambro and its strong foothold in Latin America and Asia would make Baxter an unquestioned leader, CEO Robert Parkinson has said, folding in the Swedish company's $1.6 billion and solid position in hemodialysis.

Without Gambro, Baxter projected up to 3% annual revenue growth, but, provided the deal gets done on schedule, Baxter expects to grow as much as 8% on the year, good for about $15.3 billion for 2013.

Upon signing the deal in December, Baxter figured it would close its Gambro buyout in the first half of 2013, but regulatory delays have pushed the expected wrap-up back a quarter. Baxter is still piecing together the cash it needs to get the deal done, in June announcing plans to raise $3.5 billion by selling senior notes.

 

温馨提示:87%用户都在生物谷APP上阅读,扫描立刻下载! 天天精彩!


相关标签

最新会议 培训班 期刊库